DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rhegmatogenous Retinal Detachment

Intervention: colchicine (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Shahid Beheshti Medical University

Official(s) and/or principal investigator(s):
Hamid Ahmadieh, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University

Summary

This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

proliferative vitreoretinopathy

retinal reattachment rate

Secondary outcome:

visual acuity

reoperation

macular pucker

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Rhegmatogenous retinal detachment

Exclusion Criteria:

- PVR grade C

- Duration of retinal detachment ≥ one month

- History of cataract surgery

- History of RD surgery

Locations and Contacts

Hamid Ahmadieh,MD, Tehran 16666, Iran, Islamic Republic of
Additional Information

Starting date: March 2004
Last updated: October 6, 2006

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017